Ratings
0
Nobody has rated this yet. Be the first!
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia
Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.
.svg/500px-Flag_of_the_United_States_(DDD-F-416E_specifications).svg.png)